Investments, Funding & Disinvestment

The Israeli pharmaceutical company will receive the funding over four years to support ongoing trials of the anti-TL1A antibody, which Teva is co-developing with Sanofi.

ATG-201 is designed as a bispecific molecule that binds to both CD3 on T cells and CD19 on B cells, effectively recruiting the body’s own immune system to destroy disease-causing B cells.

The new manufacturing hub represents a core strategic priority for PharmaEssentia as the company works to strengthen its supply chain, increase production flexibility, and diversify its geographic footprint.

The Japanese pharmaceutical giant expects the transaction to conclude during the first quarter of fiscal 2026, subject to standard regulatory conditions.

The tabletting facility in Athlone represents a cornerstone of Novo Nordisk’s long-term strategy to strengthen its presence in Ireland and enhance its global manufacturing footprint.

This advanced immunotherapy works by modifying a patient’s own immune cells to better identify and destroy cancer cells.

The agreement grants Novo Nordisk licensing rights to select oral drug-delivery technologies from Vivtex.

Saudi Arabia’s pharmaceutical market projects growth to USD15.6 billion by 2030, up from USD11.8 billion in 2024.

The rebrand responds to growing scientific understanding that metabolic syndrome functions as a multi-system condition rather than isolated diseases.